Substaging and Stratified Treatment of T1 Bladder Cancer - a Nationwide Register-Based Study. July 15, 2026 Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Cristina Suárez describes LITESPARK-033, a phase 3 trial addressing an unmet need in patients who progress during or within 24 months after adjuvant pembrolizumab for clear cell renal cell carcinoma.

Pedro Barata discusses systemic therapy selection and monitoring in low-volume metachronous metastatic hormone-sensitive prostate cancer. He emphasizes that low disease volume doe ...

Yudai Ishiyama presents a restricted mean survival time analysis of four IO combination regimens in advanced clear cell RCC. Using digitized Kaplan-Meier data from CheckMate 214, ...

Nectin-4 is a cell-adhesion molecule overexpressed in several malignancies and is a promising therapeutic target. Its expression profile and clinical relevance in prostate cancer (PCa) remain ...

Prostate cancer requiring radical prostatectomy surgery, invariably affects many aspects of men's lives. Whilst altered sexual function is well documented as a potential outcome of surgery, the impact ...

The majority of bladder cancers are diagnosed as non-muscle invasive (NMIBC), with 90% over the age of 55. Although the incidence of several malignancies is increasing among younger adults in whom ...

Prostate-specific antigen (PSA) testing to screen for prostate cancer is controversial. An alternative approach, Stockholm3, combines PSA, plasma protein biomarkers, polygenic risk, and clinical ...

Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...

Testicular disorders, including male infertility and hypogonadism, are increasingly prevalent and current diagnostic tools have important limitations. The testicular microcirculation underpins ...

(UroToday.com) The 2026 ASCO annual meeting featured a bladder cancer session and a presentation by Dr. Earle Burgess discussing clinical outcomes with ERBB2 gene amplification and activating ...